NSG 533 Exam 2 - Advanced Pharmacology Wilkes University | 2026/2027 Edition
NSG 533 / NSG533 EXAM 2 (LATEST ): ADVANCED PHARMACOLOGY
QUESTIONS AND VERIFIED ANSWERS | 100% CORRECT | GRADE A
Wilkes University School of Nursing | MSN/Advanced Practice Nursing
Total Questions: 100 Cognitive Levels: Recall 20% | Application 50% | Analysis 30%
Format: Multiple Choice (A-D) Style: 75% Scenario-based | 25% Direct Knowledge
Sections: 7 (Pharmacology Domains) Edition: 2026/2027 Verified
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 72-year-old male with hepatic cirrhosis is prescribed a drug that undergoes extensive first-pass
metabolism. The prescriber plans to switch from oral to sublingual administration. What is the primary
pharmacokinetic rationale for this route change?
A. Sublingual administration avoids gastric acid degradation of the drug.
B. Sublingual administration bypasses the portal circulation and first-pass hepatic metabolism, increasing
bioavailability. [CORRECT]
C. Sublingual administration slows absorption to extend the duration of action.
D. Sublingual administration improves patient compliance in elderly patients.
Correct Answer: B
Rationale: Sublingual administration delivers drug directly into the systemic circulation via the venous drainage of the oral
mucosa, bypassing the portal circulation and hepatic first-pass metabolism. In a cirrhotic patient whose hepatic metabolic
capacity is already impaired, this route can substantially increase bioavailability (often 2-5 fold for high first-pass drugs like
nitroglycerin). The other options either misidentify the mechanism (gastric acid degradation), reverse the kinetic effect (slowed
absorption), or focus on compliance rather than pharmacokinetics.
Q2: A patient on long-term phenytoin therapy for epilepsy presents with nystagmus and ataxia. Laboratory
results show a serum phenytoin level of 28 mcg/mL (therapeutic range 10-20 mcg/mL). The phenomenon most
responsible for the disproportionate rise in drug levels with dose escalation is:
A. Linear (first-order) pharmacokinetics
B. Zero-order (saturation) pharmacokinetics due to saturation of hepatic hydroxylation enzymes
[CORRECT]
C. Increased renal tubular reabsorption of the drug
D. Enhanced protein binding at higher concentrations
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (saturable) kinetics: at low doses it follows first-order kinetics, but as doses
approach the Km of hepatic CYP2C9/2C19 hydroxylation, metabolism saturates and shifts toward zero-order. Small dose
increases can cause disproportionate, even toxic, plasma concentration rises. Linear kinetics (option A) would produce
proportional changes. Renal reabsorption (option C) and protein binding (option D) do not explain the nonlinear concentration
surge characteristic of phenytoin.
Page 1 | Grade A Verified Answers | 100% Correct
,NSG 533 Exam 2 - Advanced Pharmacology Wilkes University | 2026/2027 Edition
Q3: A 68-year-old female is started on warfarin 5 mg daily. She has a serum albumin of 2.8 g/dL (normal
3.5-5.0). Which pharmacokinetic principle most directly explains the increased risk of bleeding in this patient
even with a 'therapeutic' total warfarin level?
A. Reduced hepatic CYP2C9 metabolism of warfarin
B. Decreased plasma protein binding increasing the free (active) fraction of warfarin [CORRECT]
C. Increased volume of distribution due to ascites
D. Prolonged enterohepatic recirculation of warfarin
Correct Answer: B
Rationale: Warfarin is highly protein-bound (~99%) to albumin. Hypoalbuminemia increases the free (pharmacologically
active) fraction, raising bleeding risk even when total drug concentration appears therapeutic. Total levels measure bound + free
drug; the INR (reflecting free-warfarin effect) is the clinically meaningful monitor. Options A, C, and D describe changes that
are not the primary driver in this scenario—albumin binding is the central issue.
Q4: A drug with a half-life of 12 hours is administered once daily. Approximately how long will it take to
reach approximately 95% of steady-state plasma concentration in a patient with normal hepatic and renal
function?
A. 12 hours (1 half-life)
B. 24 hours (2 half-lives)
C. 36 hours (3 half-lives)
D. 60 hours (~5 half-lives) [CORRECT]
Correct Answer: D
Rationale: Steady state is achieved after approximately 4-5 half-lives. At 5 half-lives, ~96.875% of steady state is reached. With
a t1/2 of 12 hours, 5 half-lives equals 60 hours (about 2.5 days). One half-life (50%), two (75%), and three (87.5%) are
insufficient. This principle underlies loading-dose strategy for drugs needing rapid therapeutic levels (e.g., amiodarone, digoxin,
phenytoin).
Q5: A patient receives a loading dose of digoxin followed by a maintenance dose. Which pharmacokinetic
concept directly justifies the use of a loading dose for this medication?
A. Digoxin has a narrow therapeutic index and short half-life.
B. Digoxin has a long half-life (36-48 hours), so steady state would take over a week without a loading dose.
[CORRECT]
C. Loading doses reduce the risk of digoxin toxicity.
D. Loading doses are required for all drugs given intravenously.
Correct Answer: B
Rationale: Drugs with long half-lives require an extended period (4-5 half-lives) to reach steady-state therapeutic
concentrations. Digoxin's 36-48 hour half-life means approximately 7-10 days to steady state—a delay unacceptable in acute
heart failure or atrial fibrillation with rapid ventricular response. A loading dose rapidly fills the volume of distribution to
achieve therapeutic concentration quickly. Digoxin actually has a NARROW therapeutic index (option A is wrong cause),
loading doses do NOT reduce toxicity risk (C), and loading doses are not universal (D).
Page 2 | Grade A Verified Answers | 100% Correct
,NSG 533 Exam 2 - Advanced Pharmacology Wilkes University | 2026/2027 Edition
Q6: A new drug has a therapeutic index of 4 (LD50/ED50 = 4). Compared to a drug with a therapeutic index
of 12, this new drug is best described as:
A. Safer because the lethal dose is closer to the effective dose.
B. More dangerous, requiring closer monitoring of plasma levels and patient response. [CORRECT]
C. More potent because a lower dose achieves the effect.
D. More efficacious because it produces a stronger maximal effect.
Correct Answer: B
Rationale: Therapeutic index (TI) = LD50/ED50. A low TI (e.g., 4) means the lethal and effective doses are close, requiring
meticulous dose individualization and serum concentration monitoring (e.g., digoxin, warfarin, lithium, aminoglycosides). A high
TI (e.g., 12) indicates a wide safety margin. TI does not determine potency (option C—potency is ED50 itself) or efficacy (option
D—maximal effect, Emax). Option A reverses the safety logic.
Q7: A patient has been taking diazepam chronically. Over time, the same dose produces less sedation. The
patient is exhibiting which pharmacodynamic phenomenon?
A. Tachyphylaxis—an acute, rapid loss of response
B. Tolerance—a gradual decrease in response due to receptor down-regulation or desensitization
[CORRECT]
C. Idiosyncratic reaction
D. Cumulative drug effect
Correct Answer: B
Rationale: Tolerance is a slowly developing decrease in response with continued dosing, often via receptor down-regulation
(e.g., GABA-A receptors with chronic benzodiazepines) or enzymatic induction. Tachyphylaxis (option A) is acute tolerance
developing within hours-days (e.g., nitrates, ephedrine). Idiosyncratic reactions (C) are unpredictable genetic effects; cumulative
effects (D) refer to drug accumulation from impaired elimination, not receptor adaptation.
Q8: A 56-year-old patient with chronic kidney disease (eGFR 28 mL/min/1.73m²) requires antibiotic therapy
with gentamicin. Which pharmacokinetic parameter most directly requires adjustment in this patient?
A. Absorption—the patient should switch from IV to oral therapy
B. Distribution—only loading dose changes are needed
C. Elimination—the maintenance dose interval must be extended or dose reduced [CORRECT]
D. Metabolism—hepatic enzyme induction is the primary concern
Correct Answer: C
Rationale: Gentamicin is excreted almost exclusively by glomerular filtration. Reduced eGFR prolongs elimination half-life,
increasing accumulation and nephro/ototoxicity risk. The maintenance dosing interval must be extended (or dose reduced),
guided by trough levels and renal function monitoring. Absorption is unchanged (A), distribution affects Vd only modestly (B),
and gentamicin undergoes minimal hepatic metabolism (D).
Page 3 | Grade A Verified Answers | 100% Correct
, NSG 533 Exam 2 - Advanced Pharmacology Wilkes University | 2026/2027 Edition
Q9: Naloxone is administered to reverse opioid-induced respiratory depression. Naloxone's mechanism as a
competitive antagonist means that:
A. It irreversibly binds to the mu-opioid receptor.
B. It binds reversibly to the mu-opioid receptor with no intrinsic activity, shifting the opioid dose-response
curve to the right. [CORRECT]
C. It enhances the analgesic effect of opioids.
D. It accelerates opioid metabolism, lowering plasma concentration.
Correct Answer: B
Rationale: Competitive antagonists bind reversibly to the receptor with zero intrinsic activity. They shift the agonist
dose-response curve to the right in a parallel fashion, increasing the apparent ED50. The agonist can still produce full effect if
concentration is increased sufficiently. Naloxone is a competitive mu-opioid antagonist; non-competitive antagonism (A) is
irreversible. Options C and D mischaracterize naloxone's pharmacology.
Q10: A new drug has high affinity for the target receptor but low intrinsic activity. Compared to the
endogenous agonist, this drug would be classified as a:
A. Full agonist
B. Partial agonist—producing submaximal effect even at full receptor occupancy [CORRECT]
C. Competitive antagonist with no intrinsic activity
D. Inverse agonist reducing constitutive receptor activity
Correct Answer: B
Rationale: Partial agonists bind receptors with affinity but have intrinsic activity lower than full agonists (0 < intrinsic activity <
1). Even at 100% receptor occupancy, they cannot produce the maximal response. Examples: pindolol (β-blocker with ISA),
buprenorphine (opioid), varenicline (nicotinic). In the presence of a full agonist, partial agonists behave as antagonists. Full
agonists (A) have high intrinsic activity, competitive antagonists (C) have zero intrinsic activity.
Q11: A patient develops anaphylaxis after the second dose of penicillin. This reaction is best classified as:
A. A predictable, dose-dependent adverse drug reaction (Type A)
B. A dose-independent, immunologic adverse drug reaction (Type B) [CORRECT]
C. An idiosyncratic reaction due to genetic enzyme deficiency
D. A delayed cytotoxic reaction (Type C)
Correct Answer: B
Rationale: Penicillin-induced anaphylaxis is a Type B (bizarre/idiosyncratic) adverse drug reaction: dose-independent,
immunologically mediated (IgE in this case), and not predictable from drug pharmacology. Type A reactions (A) are predictable,
dose-dependent extensions of pharmacologic action. Type C (D) represents dose- and time-dependent cumulative effects (e.g.,
amiodarone pulmonary fibrosis). Idiosyncratic enzyme deficiency (C) describes reactions like G6PD-deficiency hemolysis.
Q12: Which pharmacokinetic parameter is most useful for determining the dosing interval of a drug to
maintain therapeutic plasma concentrations?
A. Bioavailability (F)
B. Volume of distribution (Vd)
C. Half-life (t1/2) [CORRECT]
D. Clearance (Cl)
Correct Answer: C
Rationale: Half-life determines the dosing interval: a drug is typically dosed every 1 half-life to maintain therapeutic levels with
minimal peak-trough fluctuation (e.g., once-daily for t1/2 ~24h). For drugs with very short half-lives, extended-release
formulations or continuous infusion are used. Vd (B) and Cl (D) are used to calculate dose and loading dose; bioavailability (A)
determines oral dose equivalence to IV. Together, Vd and Cl determine t1/2 = 0.693 × Vd / Cl.
Page 4 | Grade A Verified Answers | 100% Correct
NSG 533 / NSG533 EXAM 2 (LATEST ): ADVANCED PHARMACOLOGY
QUESTIONS AND VERIFIED ANSWERS | 100% CORRECT | GRADE A
Wilkes University School of Nursing | MSN/Advanced Practice Nursing
Total Questions: 100 Cognitive Levels: Recall 20% | Application 50% | Analysis 30%
Format: Multiple Choice (A-D) Style: 75% Scenario-based | 25% Direct Knowledge
Sections: 7 (Pharmacology Domains) Edition: 2026/2027 Verified
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 72-year-old male with hepatic cirrhosis is prescribed a drug that undergoes extensive first-pass
metabolism. The prescriber plans to switch from oral to sublingual administration. What is the primary
pharmacokinetic rationale for this route change?
A. Sublingual administration avoids gastric acid degradation of the drug.
B. Sublingual administration bypasses the portal circulation and first-pass hepatic metabolism, increasing
bioavailability. [CORRECT]
C. Sublingual administration slows absorption to extend the duration of action.
D. Sublingual administration improves patient compliance in elderly patients.
Correct Answer: B
Rationale: Sublingual administration delivers drug directly into the systemic circulation via the venous drainage of the oral
mucosa, bypassing the portal circulation and hepatic first-pass metabolism. In a cirrhotic patient whose hepatic metabolic
capacity is already impaired, this route can substantially increase bioavailability (often 2-5 fold for high first-pass drugs like
nitroglycerin). The other options either misidentify the mechanism (gastric acid degradation), reverse the kinetic effect (slowed
absorption), or focus on compliance rather than pharmacokinetics.
Q2: A patient on long-term phenytoin therapy for epilepsy presents with nystagmus and ataxia. Laboratory
results show a serum phenytoin level of 28 mcg/mL (therapeutic range 10-20 mcg/mL). The phenomenon most
responsible for the disproportionate rise in drug levels with dose escalation is:
A. Linear (first-order) pharmacokinetics
B. Zero-order (saturation) pharmacokinetics due to saturation of hepatic hydroxylation enzymes
[CORRECT]
C. Increased renal tubular reabsorption of the drug
D. Enhanced protein binding at higher concentrations
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (saturable) kinetics: at low doses it follows first-order kinetics, but as doses
approach the Km of hepatic CYP2C9/2C19 hydroxylation, metabolism saturates and shifts toward zero-order. Small dose
increases can cause disproportionate, even toxic, plasma concentration rises. Linear kinetics (option A) would produce
proportional changes. Renal reabsorption (option C) and protein binding (option D) do not explain the nonlinear concentration
surge characteristic of phenytoin.
Page 1 | Grade A Verified Answers | 100% Correct
,NSG 533 Exam 2 - Advanced Pharmacology Wilkes University | 2026/2027 Edition
Q3: A 68-year-old female is started on warfarin 5 mg daily. She has a serum albumin of 2.8 g/dL (normal
3.5-5.0). Which pharmacokinetic principle most directly explains the increased risk of bleeding in this patient
even with a 'therapeutic' total warfarin level?
A. Reduced hepatic CYP2C9 metabolism of warfarin
B. Decreased plasma protein binding increasing the free (active) fraction of warfarin [CORRECT]
C. Increased volume of distribution due to ascites
D. Prolonged enterohepatic recirculation of warfarin
Correct Answer: B
Rationale: Warfarin is highly protein-bound (~99%) to albumin. Hypoalbuminemia increases the free (pharmacologically
active) fraction, raising bleeding risk even when total drug concentration appears therapeutic. Total levels measure bound + free
drug; the INR (reflecting free-warfarin effect) is the clinically meaningful monitor. Options A, C, and D describe changes that
are not the primary driver in this scenario—albumin binding is the central issue.
Q4: A drug with a half-life of 12 hours is administered once daily. Approximately how long will it take to
reach approximately 95% of steady-state plasma concentration in a patient with normal hepatic and renal
function?
A. 12 hours (1 half-life)
B. 24 hours (2 half-lives)
C. 36 hours (3 half-lives)
D. 60 hours (~5 half-lives) [CORRECT]
Correct Answer: D
Rationale: Steady state is achieved after approximately 4-5 half-lives. At 5 half-lives, ~96.875% of steady state is reached. With
a t1/2 of 12 hours, 5 half-lives equals 60 hours (about 2.5 days). One half-life (50%), two (75%), and three (87.5%) are
insufficient. This principle underlies loading-dose strategy for drugs needing rapid therapeutic levels (e.g., amiodarone, digoxin,
phenytoin).
Q5: A patient receives a loading dose of digoxin followed by a maintenance dose. Which pharmacokinetic
concept directly justifies the use of a loading dose for this medication?
A. Digoxin has a narrow therapeutic index and short half-life.
B. Digoxin has a long half-life (36-48 hours), so steady state would take over a week without a loading dose.
[CORRECT]
C. Loading doses reduce the risk of digoxin toxicity.
D. Loading doses are required for all drugs given intravenously.
Correct Answer: B
Rationale: Drugs with long half-lives require an extended period (4-5 half-lives) to reach steady-state therapeutic
concentrations. Digoxin's 36-48 hour half-life means approximately 7-10 days to steady state—a delay unacceptable in acute
heart failure or atrial fibrillation with rapid ventricular response. A loading dose rapidly fills the volume of distribution to
achieve therapeutic concentration quickly. Digoxin actually has a NARROW therapeutic index (option A is wrong cause),
loading doses do NOT reduce toxicity risk (C), and loading doses are not universal (D).
Page 2 | Grade A Verified Answers | 100% Correct
,NSG 533 Exam 2 - Advanced Pharmacology Wilkes University | 2026/2027 Edition
Q6: A new drug has a therapeutic index of 4 (LD50/ED50 = 4). Compared to a drug with a therapeutic index
of 12, this new drug is best described as:
A. Safer because the lethal dose is closer to the effective dose.
B. More dangerous, requiring closer monitoring of plasma levels and patient response. [CORRECT]
C. More potent because a lower dose achieves the effect.
D. More efficacious because it produces a stronger maximal effect.
Correct Answer: B
Rationale: Therapeutic index (TI) = LD50/ED50. A low TI (e.g., 4) means the lethal and effective doses are close, requiring
meticulous dose individualization and serum concentration monitoring (e.g., digoxin, warfarin, lithium, aminoglycosides). A high
TI (e.g., 12) indicates a wide safety margin. TI does not determine potency (option C—potency is ED50 itself) or efficacy (option
D—maximal effect, Emax). Option A reverses the safety logic.
Q7: A patient has been taking diazepam chronically. Over time, the same dose produces less sedation. The
patient is exhibiting which pharmacodynamic phenomenon?
A. Tachyphylaxis—an acute, rapid loss of response
B. Tolerance—a gradual decrease in response due to receptor down-regulation or desensitization
[CORRECT]
C. Idiosyncratic reaction
D. Cumulative drug effect
Correct Answer: B
Rationale: Tolerance is a slowly developing decrease in response with continued dosing, often via receptor down-regulation
(e.g., GABA-A receptors with chronic benzodiazepines) or enzymatic induction. Tachyphylaxis (option A) is acute tolerance
developing within hours-days (e.g., nitrates, ephedrine). Idiosyncratic reactions (C) are unpredictable genetic effects; cumulative
effects (D) refer to drug accumulation from impaired elimination, not receptor adaptation.
Q8: A 56-year-old patient with chronic kidney disease (eGFR 28 mL/min/1.73m²) requires antibiotic therapy
with gentamicin. Which pharmacokinetic parameter most directly requires adjustment in this patient?
A. Absorption—the patient should switch from IV to oral therapy
B. Distribution—only loading dose changes are needed
C. Elimination—the maintenance dose interval must be extended or dose reduced [CORRECT]
D. Metabolism—hepatic enzyme induction is the primary concern
Correct Answer: C
Rationale: Gentamicin is excreted almost exclusively by glomerular filtration. Reduced eGFR prolongs elimination half-life,
increasing accumulation and nephro/ototoxicity risk. The maintenance dosing interval must be extended (or dose reduced),
guided by trough levels and renal function monitoring. Absorption is unchanged (A), distribution affects Vd only modestly (B),
and gentamicin undergoes minimal hepatic metabolism (D).
Page 3 | Grade A Verified Answers | 100% Correct
, NSG 533 Exam 2 - Advanced Pharmacology Wilkes University | 2026/2027 Edition
Q9: Naloxone is administered to reverse opioid-induced respiratory depression. Naloxone's mechanism as a
competitive antagonist means that:
A. It irreversibly binds to the mu-opioid receptor.
B. It binds reversibly to the mu-opioid receptor with no intrinsic activity, shifting the opioid dose-response
curve to the right. [CORRECT]
C. It enhances the analgesic effect of opioids.
D. It accelerates opioid metabolism, lowering plasma concentration.
Correct Answer: B
Rationale: Competitive antagonists bind reversibly to the receptor with zero intrinsic activity. They shift the agonist
dose-response curve to the right in a parallel fashion, increasing the apparent ED50. The agonist can still produce full effect if
concentration is increased sufficiently. Naloxone is a competitive mu-opioid antagonist; non-competitive antagonism (A) is
irreversible. Options C and D mischaracterize naloxone's pharmacology.
Q10: A new drug has high affinity for the target receptor but low intrinsic activity. Compared to the
endogenous agonist, this drug would be classified as a:
A. Full agonist
B. Partial agonist—producing submaximal effect even at full receptor occupancy [CORRECT]
C. Competitive antagonist with no intrinsic activity
D. Inverse agonist reducing constitutive receptor activity
Correct Answer: B
Rationale: Partial agonists bind receptors with affinity but have intrinsic activity lower than full agonists (0 < intrinsic activity <
1). Even at 100% receptor occupancy, they cannot produce the maximal response. Examples: pindolol (β-blocker with ISA),
buprenorphine (opioid), varenicline (nicotinic). In the presence of a full agonist, partial agonists behave as antagonists. Full
agonists (A) have high intrinsic activity, competitive antagonists (C) have zero intrinsic activity.
Q11: A patient develops anaphylaxis after the second dose of penicillin. This reaction is best classified as:
A. A predictable, dose-dependent adverse drug reaction (Type A)
B. A dose-independent, immunologic adverse drug reaction (Type B) [CORRECT]
C. An idiosyncratic reaction due to genetic enzyme deficiency
D. A delayed cytotoxic reaction (Type C)
Correct Answer: B
Rationale: Penicillin-induced anaphylaxis is a Type B (bizarre/idiosyncratic) adverse drug reaction: dose-independent,
immunologically mediated (IgE in this case), and not predictable from drug pharmacology. Type A reactions (A) are predictable,
dose-dependent extensions of pharmacologic action. Type C (D) represents dose- and time-dependent cumulative effects (e.g.,
amiodarone pulmonary fibrosis). Idiosyncratic enzyme deficiency (C) describes reactions like G6PD-deficiency hemolysis.
Q12: Which pharmacokinetic parameter is most useful for determining the dosing interval of a drug to
maintain therapeutic plasma concentrations?
A. Bioavailability (F)
B. Volume of distribution (Vd)
C. Half-life (t1/2) [CORRECT]
D. Clearance (Cl)
Correct Answer: C
Rationale: Half-life determines the dosing interval: a drug is typically dosed every 1 half-life to maintain therapeutic levels with
minimal peak-trough fluctuation (e.g., once-daily for t1/2 ~24h). For drugs with very short half-lives, extended-release
formulations or continuous infusion are used. Vd (B) and Cl (D) are used to calculate dose and loading dose; bioavailability (A)
determines oral dose equivalence to IV. Together, Vd and Cl determine t1/2 = 0.693 × Vd / Cl.
Page 4 | Grade A Verified Answers | 100% Correct
